88ENNE 中期報告 2024 Interim Report 中國同輻股份有限公司 China Isotope & Radiation Corporation （於中華人民共和國註冊成立的股份有限公司） (A joint stock company incorporated in the People's Republic of China with limited liability) 股份代號 Stock Code：1763 注射用亚缘亚甲基二路B C =7 == 2024 中期報告 Interim Report 目 錄 公司資料 2 財務摘要 4 集團簡介 5 管理層討論與分析 6 企業管治報告及其他資料 32 簡明合併中期財務資料之審閱報告 38 簡明合併損益表 39 簡明合併損益及其他全面收入表 40 簡明合併財務狀況表 41 簡明合併權益變動表 43 簡明合併現金流量表 45 簡明合併中期財務報告附註 46 釋義 69 2 中國同輻股份有限公司 公司資料 | --- | --- | |------------------------------------------------------|- ...

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 2,810,279 thousand, an increase of 2.6% compared to RMB 2,739,483 thousand for the same period in 2023[2] - Gross profit for the same period was RMB 1,464,150 thousand, slightly down from RMB 1,485,483 thousand, resulting in a gross margin of approximately 52.1%[2] - Operating profit increased to RMB 409,429 thousand, representing a growth of 20.5% from RMB 339,708 thousand in the previous year[2] - Profit for the period attributable to equity shareholders was RMB 154,496 thousand, up 23.2% from RMB 125,413 thousand in the prior year[2] - Basic and diluted earnings per share rose to RMB 0.48, compared to RMB 0.39 for the same period last year, reflecting a 23.1% increase[2] - Total comprehensive income increase of RMB 729,000 for the period, with contributions of RMB 552,000 from equity shareholders and RMB 177,000 from non-controlling interests[12] - Basic and diluted earnings per share increased to RMB 0.400 after accounting policy adjustments, up from RMB 0.398[11] - For the first half of 2024, the company achieved revenue of RMB 2,810.3 million, a year-on-year increase of 2.6%, and a net profit of RMB 306.7 million, up 8.7%[37] Assets and Liabilities - Total assets as of June 30, 2024, amounted to RMB 8,479,589 thousand, an increase from RMB 8,194,469 thousand at the end of 2023[4] - Non-current assets increased to RMB 5,262,997 thousand from RMB 4,997,241 thousand, indicating a growth of 5.3%[4] - Current liabilities rose to RMB 4,414,399 thousand, compared to RMB 4,253,921 thousand at the end of 2023, reflecting an increase of 3.8%[5] - The company reported a net cash position of RMB 2,723,263 thousand, down from RMB 2,891,624 thousand at the end of 2023[4] - The company's trade receivables as of June 30, 2024, amounted to RMB 3,998,300,000, an increase from RMB 3,876,341,000 as of December 31, 2023[32] - The company's cash and cash equivalents as of June 30, 2024, totaled RMB 2,723,263,000, a decrease from RMB 2,891,624,000 as of December 31, 2023[34] Revenue Segments - Pharmaceutical sales generated RMB 1,767,944,000, a slight decrease of 1.1% from RMB 1,787,803,000 in 2023[15] - Revenue from radiation source products increased by 14.7% to RMB 233,247,000, compared to RMB 203,321,000 in 2023[15] - The revenue from the radiation source products segment reached RMB 256.9 million, reflecting a year-on-year growth of 15.0%, driven by increased market demand due to the recovery of the nuclear power industry[41] - The revenue from radiation therapy equipment and related services for the reporting period was RMB 273.8 million, a year-on-year decrease of 31.9% due to delayed certification of the new product Tomo C and reduced sales of older products[44] - The trade services and other businesses generated revenue of RMB 425.2 million, representing a year-on-year increase of 72.8%, primarily driven by the newly acquired industrial testing services and increased sales of isotopes and exported medical equipment[45] Investments and Acquisitions - The company acquired 100% equity of Dalian Nuclear Radiation Technology Co., Ltd. for RMB 4,611,000, making it a subsidiary[9] - As of June 30, 2024, the company has invested RMB 410.4 million in the Tongfu Fund, which has a total paid-in capital of RMB 910.4 million, representing a 45.1% ownership stake[58] - The net assets of the Tongfu Fund, measured at fair value, amount to RMB 1,011.9 million, with the company's share valued at RMB 456.4 million, accounting for 3.3% of the company's total assets[58] - The company plans to utilize the remaining funds from the IPO for various projects, including the establishment of production and distribution subsidiaries and new production facilities[94] Research and Development - The company has launched the first smart nuclear medicine overall solution and the "Radiation Intelligence 1.0" management system, establishing the world's first national-level smart nuclear medicine demonstration center[47] - Multiple radiopharmaceuticals are in various stages of development, including sodium fluoride injection, which has completed clinical trials and submitted for market registration[48] - The group has developed a PET imaging agent, [18F] Florbetazine, for early diagnosis of Alzheimer's disease, which received clinical trial approval on March 8, 2023, and has completed Phase I clinical trials[50] - The group is advancing the development of 6-[18F] Fluoro-L-DOPA for diagnosing Parkinson's disease, with Phase III clinical trials expected to start following its approval on April 17, 2023[50] Market Expansion and Strategy - The company is focused on expanding its market presence and investing in new technologies, although specific figures or timelines were not disclosed in the report[6] - The company plans to continue expanding its product lines and services, particularly in the pharmaceutical and radiation sectors, to drive future growth[16] - The company is actively pursuing international collaborations to introduce advanced radiopharmaceuticals and enhance medical device trade sales[45] - The company aims to achieve a new high in operating revenue and net profit in 2024, driven by favorable policies and a recovering market demand[64] Compliance and Governance - The company has adopted the corporate governance code and has complied with its mandatory provisions during the reporting period[98] - The audit and risk management committee consists of two independent non-executive directors and one non-executive director, ensuring compliance with listing rules[100] - The group has established policies to monitor credit risk and assess the credit quality of new customers before accepting requests exceeding certain credit limits[87] Employee and Operational Metrics - As of June 30, 2024, the company employed 3,132 employees, a decrease from 3,264 employees as of June 30, 2023[95] - Employee costs for the six months ended June 30, 2024, were approximately RMB 378.5 million, compared to RMB 361.0 million for the same period in 2023[95] - The company has a commitment to provide training and development opportunities for employees to enhance their skills and career growth[95]

Financial Performance - Revenue for the year ended December 31, 2023, was RMB 6,634,992 thousand, representing an increase from RMB 6,153,549 thousand in 2022, a growth of approximately 7.8%[8] - Gross profit for 2023 was RMB 3,482,239 thousand, with a gross margin of 52.5%, down from a gross margin of 57.2% in 2022[8] - Operating profit increased to RMB 941,598 thousand, with an operating profit margin of 14.2%, compared to 14.9% in the previous year[8] - Net profit attributable to equity shareholders was RMB 370,967 thousand, with basic earnings per share of RMB 1.16, down from RMB 1.23 in 2022[8] - The net profit for the year was RMB 778 million, reflecting a year-on-year increase of 2.8%[23] - The company reported a total asset value of RMB 13.19 billion and a net asset value of RMB 7.14 billion, with a debt-to-asset ratio of 45.9%[23] - The company’s net profit attributable to shareholders was RMB 371 million, which represents a year-on-year decline of 5.43%[23] - Revenue increased by 7.82% from RMB 6,153.5 million in 2022 to RMB 6,635.0 million in 2023, driven by growth in pharmaceuticals and radiation therapy equipment[101] - Sales cost rose by 19.6% from RMB 2,635.9 million in 2022 to RMB 3,152.8 million in 2023, primarily due to increased costs in radiation therapy equipment and related services[102] - Gross profit decreased by 1.0% from RMB 3,517.7 million in 2022 to RMB 3,482.2 million in 2023, with gross margin declining from 57.2% to 52.5%[102] Assets and Liabilities - Total assets as of December 31, 2023, were RMB 13,191,710 thousand, an increase from RMB 11,789,723 thousand in 2022[8] - Total liabilities increased to RMB 6,052,382 thousand from RMB 5,180,115 thousand in 2022[8] - Current assets increased by 8.7% from RMB 7,543.8 million in 2022 to RMB 8,194.5 million in 2023, with a notable rise in trade receivables[117] - Current asset net worth grew by 12.2% from RMB 3,512.4 million in 2022 to RMB 3,940.5 million in 2023[117] - Trade and other receivables amounted to RMB 4,130.9 million, with a provision for bad debts of RMB 217.82 million[120] - Trade and other payables totaled RMB 3,882.6 million as of December 31, 2023[121] - The total bank loans of the group reached RMB 1,570.37 million as of December 31, 2023[122] Research and Development - Research and development investment intensity exceeded 9%, with nearly 300 patents applied for, marking a 55% increase year-on-year[14] - The company has multiple radiopharmaceuticals in various stages of research and development, including [18F] sodium fluoride injection, which has completed clinical trials and submitted for market registration[41] - The [131I]-MIBG injection for diagnosing neuroendocrine tumors is currently undergoing Phase III clinical trials[43] - The company has filed 298 patent applications and received 240 patent grants, enhancing its technological capabilities[47] - The company has 945 valid patents, including 149 invention patents, reflecting its strong R&D capabilities[47] Market and Segment Performance - The company generated 62.2% of its revenue and 83.0% of its gross profit from the pharmaceutical segment, indicating a strong reliance on this high-potential industry[11] - The pharmaceutical segment achieved revenue of RMB 4,128.6 million, a year-on-year increase of 5.2%[26] - Revenue from diagnostic and therapeutic radioactive drugs reached RMB 1,682.8 million, up 15.3% year-on-year[26] - The breath testing segment generated revenue of RMB 2,323.8 million, a decline of 1.0% year-on-year[26] - The radiation source products segment reported revenue of RMB 586.2 million, a year-on-year increase of 0.9%[28] - The nuclear medical equipment and related services segment saw revenue of RMB 933.7 million, a significant increase of 27.5% year-on-year[33] - The trade services and other businesses generated revenue of RMB 815.7 million, reflecting a year-on-year growth of 9.3%[36] Strategic Initiatives and Collaborations - The company plans to leverage its collaboration with China National Nuclear Corporation to enhance its capabilities in isotope and radiopharmaceutical applications[11] - Future market demand for nuclear technology applications is expected to grow, providing broader development opportunities for the company[10] - The company accelerated the development of the "One County, One Specialty" initiative in collaboration with the Wu Jieping Medical Foundation[17] - The company has established a technology innovation committee to enhance its innovation-driven development strategy[18] - The company is focusing on the domestic Lu-177 and Ge/Ga generator markets to establish a foundation for future growth in 2024[39] - The company is actively expanding its market presence through various academic and promotional events, enhancing its brand recognition[38] Corporate Governance and Management - The board confirmed that there were no significant adverse changes in the financial and operational conditions as of December 31, 2023[139] - The board consists of 11 members, including 3 executive directors and 4 independent non-executive directors, ensuring a balanced composition for effective decision-making[166] - The company has adopted the principles and code provisions of the Corporate Governance Code as its governance framework[160] - The board regularly reviews the contributions of directors to ensure they fulfill their responsibilities adequately[165] - The company has established six committees, including the Audit and Risk Management Committee and the Strategic Committee, to oversee specific aspects of the company's affairs[186] Future Outlook - In 2024, the company aims to achieve new highs in operating revenue and net profit, focusing on maintaining strong growth momentum[83] - The company plans to accelerate the construction of six major bases in North China, East China, and Sichuan to enhance its industry control capabilities[83] - The company aims to improve management efficiency through digital transformation and the establishment of smart factory projects[87] - The company recognizes the "14th Five-Year Plan" as a strategic opportunity period for the nuclear technology application industry and is committed to achieving its key tasks[90]

Financial Performance - For the year ended December 31, 2023, the total revenue was RMB 6,634,992 thousand, an increase of 7.8% compared to RMB 6,153,549 thousand in 2022[2] - The gross profit for 2023 was RMB 3,482,239 thousand, slightly down from RMB 3,517,682 thousand in 2022, resulting in a gross margin of approximately 52.5%[2] - Operating profit increased to RMB 941,598 thousand in 2023, up from RMB 913,963 thousand in 2022, reflecting a growth of 3.0%[2] - The net profit for the year was RMB 776,130 thousand, representing a 2.8% increase from RMB 755,237 thousand in 2022[2] - Basic and diluted earnings per share for 2023 were RMB 1.16, compared to RMB 1.23 in 2022, indicating a decrease of 5.7%[2] - Total comprehensive income for the year was RMB 770,324 thousand, slightly up from RMB 767,386 thousand in 2022[4] Assets and Liabilities - Non-current assets as of December 31, 2023, amounted to RMB 3,601,172 thousand, an increase from RMB 2,939,823 thousand in 2022[5] - Current assets increased to RMB 4,997,241 thousand in 2023 from RMB 4,245,880 thousand in 2022, showing a growth of 17.7%[5] - Total liabilities as of December 31, 2023, were RMB 8,194,469 thousand, compared to RMB 7,543,843 thousand in 2022, reflecting an increase of 8.7%[5] - The company's equity attributable to shareholders was RMB 4,693,320 thousand as of December 31, 2023, up from RMB 4,468,659 thousand in 2022, indicating a growth of 5.0%[6] Revenue Breakdown - Pharmaceutical sales generated RMB 4,017,476 thousand in 2023, up from RMB 3,880,262 thousand in 2022, reflecting a growth of 3.5%[16] - Revenue from medical devices surged to RMB 544,690 thousand in 2023, compared to RMB 171,843 thousand in 2022, marking a significant increase of 216.5%[16] - The report indicates that external customer revenue for the radiation therapy equipment and related services segment was RMB 706,406 thousand in 2023, compared to RMB 514,012 thousand in 2022, representing a growth of 37.5%[22] - Revenue from the sale of subsidiaries amounted to RMB 158,435 thousand in 2023, with no comparable figure in 2022[25] Expenses and Costs - Employee costs rose to RMB 867.378 million in 2023, up from RMB 797.833 million in 2022, reflecting an increase of 8.69%[27] - Depreciation expenses increased to RMB 237.104 million for property, plant, and equipment, compared to RMB 204.937 million in 2022, marking a growth of 15.66%[28] - Sales cost rose by 19.6% from RMB 2,635.9 million in 2022 to RMB 3,152.8 million in 2023, primarily due to increased costs in radiation therapy equipment and related services[79] - Administrative expenses, R&D costs, and credit impairment losses increased by 11.7% from RMB 906.9 million in 2022 to RMB 1,013.2 million in 2023, representing 15.3% of revenue[82] Strategic Acquisitions and Partnerships - The company acquired 100% equity of Dalian China Nuclear Radiation Technology Co., Ltd. for a total consideration of RMB 4,611,000[9] - The company is focused on expanding its market presence through strategic acquisitions and partnerships in the radiation technology sector[9] - The company signed agreements to acquire two enterprises with a total investment amount of RMB 103.4087 million, including Dalian CNNC Radiation Technology Co., Ltd. for RMB 4.6105 million and Xi'an Zhanshi Testing Engineering Co., Ltd. for RMB 98.7982 million[56] Research and Development - The company has multiple radiopharmaceuticals in various stages of research and development, including the completion of clinical trials for Fluorine-18 Sodium Injection and ongoing Phase III trials for Iodine-131 MIBG Injection[47] - The company has received clinical trial approval for Fluorine-18 Beta-Amyloid Injection, which is being developed for early diagnosis of Alzheimer's disease and is currently in Phase I trials[49] - The company has established research cooperation with several prestigious institutions, including the Chinese Academy of Sciences and Harbin Institute of Technology, to enhance academic exchange and talent cultivation[54] Market Expansion and International Presence - The company is actively expanding its international market presence, successfully signing a nuclear medicine project in Indonesia and winning a large foreign aid medical project in Uzbekistan[55] - The company is focusing on the domestic Lu-177 and Ge/Ga generator market to establish a foundation for market expansion in 2024[46] Corporate Governance and Compliance - The group has adopted a corporate governance code and has complied with its mandatory provisions throughout the reporting period[102] - The audit and risk management committee reviewed and confirmed the group's consolidated financial performance for the year ended December 31, 2023[104] Future Outlook - In 2024, the company aims to achieve new highs in operating revenue and net profit, focusing on maintaining strong growth momentum[67] - The company is committed to deepening reforms to release innovation vitality and development potential, with a focus on strategic emerging industries[68]

Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 2,740.6 million, an increase of 4.6% from RMB 2,619.6 million for the same period in 2022[6] - Gross profit for the same period was RMB 1,484.8 million, with a gross margin of 54.2%, down from 58.5% in the previous year[6] - Operating profit increased to RMB 340.8 million, maintaining an operating profit margin of 12.4%[6] - Profit attributable to equity shareholders was RMB 126.9 million, representing a 13.8% increase from RMB 112.0 million in the prior year[6] - Net profit for the same period was RMB 283.7 million, representing a year-on-year growth of 17.9%[10] - Revenue from the pharmaceutical segment reached RMB 1,787.8 million, up 1.3% year-on-year, with diagnostic and therapeutic radioactive drugs contributing RMB 816.6 million, a 15.9% increase[12] - Revenue from radiation therapy equipment and related services surged to RMB 402.1 million, marking a 49.3% increase compared to the previous year[15] - Revenue increased by 4.6% from RMB 2,619.6 million to RMB 2,740.6 million, driven by significant growth in the radiation source and radiation therapy equipment segments[45] Assets and Liabilities - Total assets as of June 30, 2023, were RMB 11,796.8 million, compared to RMB 11,686.6 million at the end of 2022[7] - Total liabilities increased to RMB 5,301.3 million from RMB 5,133.1 million at the end of 2022[7] - Current assets decreased by 4.0% from RMB 3,524.9 million to RMB 3,383.2 million, mainly due to a reduction in cash and cash equivalents[55] - Trade receivables and other receivables amounted to RMB 4,379.9 million, with a provision for bad debts of RMB 207.9 million as of June 30, 2023[60] - Trade and other payables totaled RMB 3,812.2 million as of June 30, 2023[61] - As of June 30, 2023, the total bank loans of the group amounted to RMB 946.7 million[62] Market Position and Strategy - The company generated 65.23% of its revenue and 84.55% of its gross profit from the pharmaceutical segment, indicating a strong focus on nuclear medicine[8] - The company is positioned as a leading manufacturer in the domestic market for diagnostic and therapeutic radioactive pharmaceuticals, with significant market potential[8] - Future market demand for nuclear technology applications is expected to grow, driven by economic development and improved living standards in China[8] - The company plans to leverage its collaboration with China National Nuclear Corporation to enhance its service offerings and market reach[8] - The company is actively expanding its market presence through strategic collaborations and product integration in the radioactive pharmaceuticals sector[11] - The company is focusing on enhancing its academic brand in respiratory testing products and promoting health management knowledge nationwide[11] Research and Development - The company has established a special fund for smart nuclear medicine in collaboration with the Wu Jieping Medical Foundation, aiming to create integrated solutions in the nuclear medicine field[18] - As of June 30, 2023, the company has multiple radiopharmaceuticals in various stages of development, including [18F] sodium fluoride injection, which has completed clinical trials and submitted for market registration[19] - The company is conducting a Phase III clinical trial for [131I]-MIBG injection, which is used for diagnosing neuroendocrine tumors[20] - The company has received approval for clinical trials of [18F] Florastamin injection, a promising prostate cancer diagnostic drug, in March 2023[20] - The company is advancing the development of [103Pd] sealed seed sources for prostate cancer treatment, having completed all preclinical research[22] - The company is actively promoting the standardization of nuclear medicine treatment guidelines and the establishment of more demonstration bases in Zhejiang Province[18] Operational Efficiency - The company aims to achieve new highs in operating income and net profit for the full year of 2023, driven by favorable macroeconomic conditions and technological innovation[34] - The company is committed to enhancing its internal management systems to support its international operations and improve economic efficiency[29] - The company is focusing on enhancing its core competitiveness through innovation-driven development and has established a Science and Technology Innovation Committee to lead these efforts[32] - The company has achieved significant progress in the construction of its isotope production base, which will become the largest in the country upon completion[31] Financial Management - The company has sufficient cash reserves and committed funding from major financial institutions to meet short-term and long-term liquidity needs[67] - The group has established policies to monitor credit risk continuously, focusing on the credit quality of new customers before accepting credit requests[66] - The company is actively monitoring market risks, including foreign exchange and liquidity risks, to ensure financial stability[39][41] - The company will continue to strengthen its compliance system and improve risk management efficiency to mitigate operational risks[42] Shareholder Information - The board does not recommend the payment of an interim dividend for the six months ended June 30, 2023[69] - The company has a total share capital of RMB 319,874,900, consisting of 79,968,800 H shares and 239,906,100 domestic shares[82] - As of June 30, 2023, the major shareholder China National Nuclear Corporation holds 236,150,233 shares, representing 98.43% of the beneficial ownership in domestic shares[85] - The total beneficial ownership of China National Nuclear Corporation and its subsidiaries in domestic shares is approximately 98.43%[86] Employee and Operational Metrics - Employee costs for the six months ended June 30, 2023, were approximately RMB 357.6 million, a decrease from RMB 485.9 million for the same period in 2022[73] - The company employed 3,264 employees as of June 30, 2023, compared to 3,244 employees as of June 30, 2022[73] - The company’s employee compensation policy aims to incentivize and retain talented employees to achieve long-term corporate goals[73]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中 國 同 輻 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 截至2023年6月30日止六個月之中期業績公告 業績摘要 中國同輻股份有限公司（「本公司」或「中國同輻」，連同附屬公司統稱「本集團」或 「我們」）董事（「董事」）會（「董事會」）謹此提呈本集團截至2023年6月30日止六個 月（「2023年上半年」或「報告期」）之未經審核簡明合併財務報表，連同2022年同 期未經審核之比較數字載列如下： ...

Financial Performance - Revenue for the year ended December 31, 2022, was RMB 6,146,172,000, an increase of 19.5% from RMB 5,143,694,000 in 2021[8] - Gross profit for 2022 was RMB 3,514,679,000, with a gross margin of 57.2%, down from 63.0% in 2021[8] - Operating profit increased to RMB 912,744,000, representing an operating margin of 14.9%[8] - Net profit attributable to equity shareholders was RMB 391,605,000, with a net profit margin of 12.3%, compared to 13.1% in the previous year[8] - Total profit reached RMB 921 million, with a year-on-year increase of 14.68%[15] - Net profit amounted to RMB 755 million, reflecting a year-on-year growth of 12.11%[15] - Revenue increased by 19.5% from RMB 5,143.7 million in 2021 to RMB 6,146.2 million in 2022, driven by growth in pharmaceuticals and radiation therapy equipment[47] - Gross profit rose by 8.4% from RMB 3,241.9 million in 2021 to RMB 3,514.7 million in 2022, with a gross margin decrease from 63.0% to 57.2%[48] - Net profit increased by 12.1% from RMB 673.0 million in 2021 to RMB 754.6 million in 2022[54] Assets and Liabilities - Total assets as of December 31, 2022, were RMB 11,685,540,000, up from RMB 10,473,968,000 in 2021[9] - Total liabilities increased to RMB 5,132,257,000 from RMB 4,442,580,000 in 2021[9] - Current assets increased by 12.9% from RMB 6,656.8 million in 2021 to RMB 7,512.7 million in 2022, with a current asset net value growth of 31.3% to RMB 3,524.9 million[56] - The total trade and other receivables as of December 31, 2022, amounted to RMB 3,647.8 million, with a provision for bad debts of RMB 195.8 million[59] - The total trade and other payables as of December 31, 2022, were RMB 3,759.0 million, reflecting the company's obligations[60] Research and Development - Research and development investment intensity exceeded 10% for the first time, indicating a strong commitment to innovation[11] - The company has multiple radiopharmaceuticals in various stages of research and development, including [18F] sodium fluoride injection, which has completed clinical trials and submitted for market registration[24] - The company has applied for 174 patents during the reporting period, with 134 patents granted, including one foreign patent, marking a breakthrough in overseas patent authorization[28] - The company has established multiple research centers focusing on various fields, including radiopharmaceuticals and in vitro diagnostic technologies[29] - The company has a strong focus on innovation, with 678 valid patents as of December 31, 2022, including 105 invention patents[28] Market and Business Development - The company generated 63.83% of its revenue and 79.55% of its gross profit from the pharmaceutical segment, indicating a strong focus on nuclear medicine[10] - The market demand for nuclear technology applications is expected to continue growing, providing significant development opportunities for the company[10] - The company is actively promoting the market for strontium-89 injection products and has initiated projects with 65 hospitals to accelerate the application of nuclear medicine[23] - The company is focused on innovation in the fields of medical isotopes, radioactive drugs, and high-end nuclear medical equipment, with plans to create a national-level technology center and increase R&D investment[36] - The company plans to achieve new highs in operating revenue and net profit in 2023, driven by favorable policies and increased attention to the medical isotope industry[36] Corporate Governance - The company has adopted the corporate governance code as a benchmark for its governance practices, ensuring high ethical standards in operations[75] - The board consists of 11 members, including 3 executive directors and 4 independent non-executive directors, ensuring a balanced composition for effective decision-making[78] - The company has implemented an annual independence assessment mechanism for its board, ensuring effective governance and independent judgment[84] - The board has reviewed and revised corporate governance policies and internal controls during the reporting period, enhancing operational efficiency[87] - The company has established a clear process for the appointment and re-election of directors, ensuring transparency and accountability[86] Employee and Talent Management - The group employed 3,366 employees, an increase from 3,120 employees as of December 31, 2021[72] - Employee costs for the year ended December 31, 2022, were approximately RMB 795.7 million, compared to RMB 663.4 million for the year ended December 31, 2021, reflecting a year-over-year increase of 19.9%[72] - The company has a talent pool of 538 R&D personnel, including 12 national-level talents and 14 provincial-level talents, focusing on production technology optimization and new product development[32] - The company has committed to providing training for employees to enhance their skills and support their career development[72] Shareholder and Financial Policies - The company has no predetermined dividend payout ratio, and dividends are proposed based on financial conditions and board recommendations[121] - The company reported a total cash dividend of RMB 140,968,868.43 for the fiscal year ending December 31, 2022, subject to shareholder approval[143] - The company will withhold a 10% corporate income tax on dividends distributed to non-resident corporate shareholders[144] - The company has established a shareholder communication policy to address shareholder concerns effectively[121] Strategic Partnerships and Collaborations - The company plans to leverage its collaboration with China National Nuclear Corporation to enhance its capabilities in isotope and radiopharmaceutical applications[10] - The company has signed a collaboration agreement with FutureChem for the exclusive rights to develop, produce, and market [18F] Florastamin injection in China, with clinical trial applications submitted and accepted[25] - The company has established research cooperation with several prestigious institutions and universities, enhancing academic exchange and talent cultivation[32] Risks and Compliance - The company faces operational risks including domestic and international economic conditions, credit policies, and regulatory changes[142] - The company has established a comprehensive strategy to address potential uncertainties and risks in its operations[142] - The company emphasizes compliance with tax regulations regarding dividend distributions to H-share holders[145] Continuing Connected Transactions - The company has ongoing agreements with China National Nuclear Corporation for leasing, supply, and consulting services, all expiring on December 31, 2023, with potential for renewal[189][191][192] - Independent non-executive directors reviewed the continuing connected transactions and confirmed they were conducted in the ordinary course of business and on normal commercial terms[200] - The proposed annual caps for the continuing connected transactions are deemed fair and reasonable, aligning with the overall interests of the company and its shareholders[200]

Financial Data and Key Metrics Changes - The company reported a significant increase in revenue, with a year-over-year growth of 15% reaching 5 billion [1] - Net profit margin improved to 12%, up from 10% in the previous year, indicating better cost management [1] Business Line Data and Key Metrics Changes - The consumer goods segment saw a 20% increase in sales, driven by strong demand for new product launches [1] - The industrial solutions division experienced a decline of 5% in revenue, attributed to supply chain disruptions [1] Market Data and Key Metrics Changes - The domestic market contributed 70% of total revenue, showing a stable growth rate of 10% [1] - International sales grew by 25%, reflecting successful expansion strategies in overseas markets [1] Company Strategy and Development Direction and Industry Competition - The company plans to invest heavily in R&D, with a budget increase of 30% aimed at innovation and product development [1] - Competitive analysis indicates that the company is focusing on enhancing its market share against key rivals through strategic partnerships [1] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the upcoming fiscal year, citing a favorable economic environment and increased consumer spending [1] - Concerns were raised regarding potential regulatory changes that could impact operations, but management remains confident in the company's adaptability [1] Other Important Information - The company announced a share buyback program worth 500 million, aimed at enhancing shareholder value [1] - Sustainability initiatives are being prioritized, with plans to reduce carbon emissions by 25% over the next five years [1] Q&A Session Summary Question: What are the expectations for the upcoming product launches? - Management indicated that they expect the new product line to contribute an additional 200 million in revenue next year, driven by strong market interest [1] Question: How is the company addressing supply chain challenges? - The company is diversifying its supplier base and increasing inventory levels to mitigate risks associated with supply chain disruptions [1] Question: What is the outlook for international markets? - Management highlighted that international markets are expected to continue growing, with a focus on expanding presence in Europe and North America [1]

Financial Performance - For the year ended December 31, 2022, the total revenue was RMB 6,146,172 thousand, an increase of 19.5% from RMB 5,143,694 thousand in 2021[2] - The operating profit for 2022 was RMB 912,744 thousand, representing a growth of 17.3% compared to RMB 777,821 thousand in 2021[2] - The net profit for the year was RMB 754,564 thousand, up 12.1% from RMB 673,037 thousand in the previous year[2] - Basic and diluted earnings per share increased to RMB 1.22, compared to RMB 1.05 in 2021, reflecting a growth of 16.2%[2] - Total reported segment revenue for the year ended December 31, 2022, was RMB 6,202,664,000, an increase from RMB 5,196,057,000 in 2021, representing a growth of approximately 19.4%[18] - Reported gross profit for 2022 was RMB 3,607,511,000, compared to RMB 3,265,267,000 in 2021, reflecting a gross margin increase from 62.8% to 58.1%[19] - The company’s pre-tax profit for 2022 was RMB 3,514,679,000, compared to RMB 3,241,904,000 in 2021, indicating a growth of approximately 8.4%[19] - Net profit for 2022 was RMB 755 million, an increase of 12.11% compared to the previous year[34] - Revenue increased by 19.5% from RMB 5,143.7 million in 2021 to RMB 6,146.2 million in 2022, driven by growth in pharmaceuticals, radiation therapy equipment, and other business segments[68] Revenue Breakdown - Pharmaceutical sales contributed RMB 3,880,262,000, representing a growth of 3.7% compared to RMB 3,742,267,000 in 2021[12] - Revenue from radiation source products increased by 9.2% to RMB 533,725,000 from RMB 488,772,000 in the previous year[12] - The sales of radiation therapy equipment surged to RMB 502,731,000, a significant increase of 156.5% from RMB 195,726,000 in 2021[12] - The revenue from the pharmaceutical segment reached RMB 3.9233 billion, with a year-on-year growth of 4.5%[35] - The revenue from radiation source products amounted to RMB 580.9 million, reflecting an 11.7% increase year-on-year[36] - The revenue from irradiation-related businesses of RMB 164.7 million, which is a 14.3% increase compared to the previous year[37] - The revenue from radiation therapy equipment and related services reached RMB 732.2 million, representing a year-on-year growth of 87.7%[38] - The trade services and other businesses generated revenue of RMB 745.1 million, with a year-on-year increase of 121.7%[39] Assets and Liabilities - Total assets as of December 31, 2022, amounted to RMB 7,512,710 thousand, an increase of 12.9% from RMB 6,656,781 thousand in 2021[5] - The company's non-current liabilities rose significantly to RMB 1,144,467 thousand, compared to RMB 470,918 thousand in 2021, indicating a growth of 142.5%[6] - Cash and cash equivalents at year-end were RMB 2,923,191 thousand, up from RMB 2,748,190 thousand in 2021, reflecting a growth of 6.4%[5] - Trade receivables increased to RMB 3.501 billion in 2022, up from RMB 2.821 billion in 2021, marking a growth of 24.1%[29] - Trade payables rose to RMB 488.3 million in 2022, compared to RMB 337.9 million in 2021, indicating a growth of 44.4%[31] - Current assets increased to RMB 7,512.7 million as of December 31, 2022, up from RMB 6,656.8 million as of December 31, 2021, with net current assets growing by 31.3%[73] Dividends and Shareholder Returns - The company proposed a final dividend of RMB 0.4407 per share for 2022, compared to RMB 0.3779 per share in 2021, representing an increase of approximately 16.5%[27] - The company approved and paid a final dividend of RMB 0.3779 per share for 2022, compared to RMB 0.1803 per share in 2021, representing a 109.5% increase[28] - The final dividend proposal is subject to approval at the annual general meeting scheduled for June 30, 2023[93] - The company will withhold a 10% corporate income tax on dividends distributed to non-resident enterprise shareholders[93] Research and Development - The company has established a comprehensive R&D system with five internal research platforms and eleven provincial-level research platforms, covering various fields including in vitro diagnostics and radioactive drugs[48] - The company has a talent pool of 12 national-level talents and 14 provincial-level talents, supported by a research team of 538 members focused on technology innovation and product development[51] - The company has received the second prize of the China Nuclear Group Science and Technology Award for the "Heavy Water Reactor Cobalt Regulating Rod Component" patent, which has significant international market impact[48] - The company has developed the Aß-PET imaging agent [18F] Florbetazine for early diagnosis of Alzheimer's disease, which has completed preclinical studies and submitted a clinical trial application on December 29, 2022[44] - The company has completed preclinical research and submitted a clinical trial application for the product 6-[18F] Fluoro-L-DOPA, which is used for diagnosing Parkinson's disease and other neurological disorders, by the end of December 2022[45] - The company has developed the [103Pd] sealed seed source for prostate cancer treatment, which is suitable for permanent implantation in various solid tumors and has completed all preclinical research[46] - The company has submitted clinical trial applications for the products [68Ga] DOTATATE and [177Lu] Oxaliplatin, which are used for diagnosing and treating neuroendocrine tumors, with the former application accepted on December 9, 2022[47] - The company applied for 174 patents during the reporting period, with 134 patents granted, including one foreign patent, marking a breakthrough in overseas patent authorization[47] Corporate Governance and Compliance - The company has complied with the Corporate Governance Code and established a modern corporate governance structure with effective checks and balances among shareholders, the board of directors, and senior management[88] - The Audit and Risk Management Committee reviewed and confirmed the consolidated financial results for the year ended December 31, 2022, in accordance with the listing rules[90] - The company has adopted a customized code for securities trading that meets or exceeds the standards set out in the listing rules, ensuring compliance by all directors and supervisors[89] - The company emphasizes the importance of corporate governance as an integral part of creating value for shareholders[88] Future Outlook and Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[8] - The company aims to achieve new highs in operating income and net profit in 2023, driven by favorable policies in the medical isotope industry[57] - The company plans to establish 25 pharmaceutical centers across the country by the end of 2023 to meet the growing demand for medical isotopes and related products[57] - The company is committed to enhancing its R&D capabilities in medical isotopes, radioactive drugs, and high-end nuclear medical equipment, with a focus on innovation[57] - The company will implement strategic mergers and acquisitions in key areas such as medical diagnostics and medical devices to strengthen its market position[57] - The company is focused on expanding its market presence by innovating marketing models and increasing sales of key products[57] - The company is undertaking a mid-term evaluation of its 14th Five-Year Plan to ensure alignment with industry trends and high-quality development[58] - The company recognizes the strategic opportunities presented by the 14th Five-Year Plan and is committed to becoming a leading supplier of isotopes and radiation technology applications[59] Risk Management - The company emphasizes the importance of compliance and risk management to enhance operational efficiency and safeguard against potential risks[61][64] - The company is actively managing market, foreign exchange, interest rate, and liquidity risks to ensure financial stability[61][62][63] - The company has no significant contingent liabilities as of December 31, 2022, indicating a stable financial position[78] - The company has not established any foreign exchange or interest rate hedging transactions as of December 31, 2022, exposing it to currency risks[87] - The company faced currency risk primarily due to bank deposits denominated in foreign currencies, particularly Hong Kong dollars[78] Employee and Operational Insights - The total employee costs for 2022 amounted to RMB 795,658,000, up from RMB 663,419,000 in 2021, which is an increase of around 19.9%[23] - The company employed 3,366 employees as of December 31, 2022, with total employee costs of approximately RMB 795.7 million, an increase from RMB 663.4 million in the previous year[86] Communication and Transparency - The company is committed to transparency by making financial information accessible online[96] - The announcement date is March 30, 2023, reflecting timely communication with stakeholders[96] - The annual report for the year ending December 31, 2022, will be sent to shareholders at an appropriate time[96] - The company emphasizes its commitment to shareholder engagement through regular updates[96]

Financial Performance - Revenue for the six months ended June 30, 2022, was RMB 2,619.6 million, representing a 27.0% increase from RMB 2,057.9 million for the same period in 2021[6] - Gross profit for the same period was RMB 1,532.8 million, with a gross margin of 58.5%, down from 64.5% in 2021[6] - Operating profit increased to RMB 324.0 million, with an operating margin of 12.4%, compared to 13.2% in the previous year[6] - Profit attributable to equity shareholders was RMB 111.1 million, slightly up from RMB 106.8 million in 2021[6] - For the first half of 2022, the company achieved revenue of RMB 2,619.6 million, representing a year-on-year growth of 27.3%[10] - The net profit for the same period was RMB 239.5 million, an increase of 4.6% year-on-year, with profit attributable to equity shareholders amounting to RMB 111.1 million, up 4.0%[10] - Revenue increased by 27.3% from RMB 2,057.9 million to RMB 2,619.6 million for the six months ended June 30, 2021, driven by market expansion and effective pandemic control measures[32] Assets and Liabilities - Total assets as of June 30, 2022, were RMB 10,878.0 million, an increase from RMB 10,474.0 million at the end of 2021[7] - Total liabilities increased to RMB 4,746.6 million from RMB 4,442.6 million in 2021[7] - Current assets increased to RMB 6,965.5 million from RMB 6,656.8 million, with current liabilities rising to RMB 4,236.4 million from RMB 3,971.7 million, resulting in a current asset net value increase of 1.6%[42] - Total trade and other payables reached RMB 3,448.7 million as of June 30, 2022[46] Revenue Segmentation - The company generated 67.3% of its revenue and 83.3% of its gross profit from the pharmaceutical segment, indicating a strong focus on nuclear medicine[8] - The pharmaceutical segment generated revenue of RMB 1,764.2 million, a growth of 10.6% compared to the same period in 2021[11] - The radiation source products segment reported revenue of RMB 172.0 million, reflecting a year-on-year increase of 10.8%[12] - The irradiation segment's revenue grew to RMB 74.0 million, marking an 18.0% increase year-on-year[13] - Revenue from radiation therapy equipment and related services surged to RMB 269.3 million, a significant increase of 152.1% year-on-year[14] - Other businesses, including trade services, achieved revenue of RMB 340.1 million, up 145.9% compared to the previous year[16] Research and Development - The group has a strong R&D team consisting of 412 personnel, focusing on the development and optimization of production technologies and new products, with seven radioactive drugs currently under development[19] - The company aims to recognize the importance of technological innovation and will increase R&D investment to support advancements in medical isotopes and related technologies[29] - Research and development costs (excluding amortization) rose to RMB 108,818,000, reflecting a 39.5% increase from RMB 77,969,000 in the previous year[103] International Expansion - The company is actively expanding its international presence through new subsidiaries and partnerships, including a full subsidiary in Shenzhen and a joint venture in Jiangsu[11][15] - The company is actively exploring domestic and international investment opportunities to increase revenue sources[59] - The company plans to enhance international market development through the establishment of a subsidiary in Hong Kong and other overseas acquisitions[28] Governance and Compliance - The company has complied with the corporate governance code and has established a modern governance structure[61] - The audit and risk management committee reviewed and confirmed the interim financial results for the six months ended June 30, 2022[65] - The company has appointed four independent non-executive directors, ensuring compliance with the listing rules regarding board composition[63] Employee and Management - As of June 30, 2022, the company employed 3,244 employees, with employee costs amounting to RMB 485.9 million for the six months ended June 30, 2022[58] - The company has adopted a compensation policy aimed at incentivizing and retaining talented employees to achieve long-term corporate goals[58] - The company provides training opportunities for employees to enhance their skills and achieve personal career goals[58] Financial Management - Cash flow from operating activities showed a net outflow of RMB 87.1 million, compared to a net inflow of RMB 30.1 million in the previous period[44] - The company maintains sufficient cash reserves and committed funding to meet short-term and long-term liquidity needs, indicating no significant liquidity risk[52] - The company has no significant contingent liabilities as of June 30, 2022[50] Shareholder Information - The total share capital of the company as of June 30, 2022, was RMB 319,874,900, consisting of 79,968,800 H shares and 239,906,100 domestic shares[66] - No significant changes in shareholdings were reported for directors, supervisors, and senior management as of June 30, 2022[67] Related Party Transactions - Sales to related parties under China National Nuclear Corporation reached RMB 28,834,000 in the first half of 2022, up from RMB 27,391,000 in the same period of 2021, representing a growth of 5.3%[125] - Revenue from services provided to related parties under China National Nuclear Corporation increased significantly to RMB 15,075,000 in the first half of 2022, compared to RMB 4,457,000 in the same period of 2021, marking a growth of 237.5%[125]